Analysts think Amgen is fairly priced

Amgen 's stock price seems, partly because of the recent share price rises, to be in line with most of the estimates. Most of the analysts say Amgen is fairly priced now. Currently the company is being followed by 8 analysts. The average of the current target prices for the stock equals 192,5 USD. This is around 3 percent more than the current price of 190,13 USD.

Estimates for Amgen not very concentrated

Over the current book year the total revenue will be 22,61 billion USD (consensus estimates). This is slightly lower than 2016's revenue of 22,85 billion USD.

Historical revenues and results Amgen plus estimates 2018

The analysts expect for 2018 a net profit of 9,34 billion USD. According to most of the analysts the company will have a profit per share for this book year of 13,41 USD. The PE-ratio therefore is 14,18.

Per share the analysts expect a dividend of 5,08 USD per share. The dividend yield is then 2,67 percent. The average dividend yield of the biotech companies equals a moderate 1 percent.

Recent target prices around 197 USD

The most recent recommendations for the biotech company are from Cowen and Company, Morgan Stanley and Piper Jaffray.

Amgen 's market capitalization is based on the number of outstanding shares around 140,35 billion USD.

Historical stock prices Amgen period 2007-2018

On Sunday the stock closed at 190,13 USD.

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.